Conclusions:
In specific groups of neutropenic patients treated for haematological malignancies, itraconazole prophylaxis could potentially reduce overall healthcare expenditure, without harming effectiveness, in settings where fluconazole is common practice in the prophylaxis of invasive fungal infections.
Fungal infections are frequent complications in sive fungal infections in immunocompromized patients. In addition, itraconazole was compared with neutropenic patients treated for haematological maan option of 'no prophylaxis'. As probabilistic analignancies. There has been a large increase in the lysis has became the state-of-the-art in cost-effecincidence of invasive fungal infections over the last tiveness analysis, a probabilistic decision-analytic 2 decades as a result of the increased number of model was used. This cost-effectiveness analysis patients who become immunocompromized as a was carried out for two different countries: Germany result of chemotherapy or the underlying disease. [1, 2] and The Netherlands. In Europe and North America, the main causative agents are Aspergillus and Candida species. The Methods incidence rate of these fungal infections depends, among other things, on the duration of neutropenia, A probabilistic decision-tree model was designed the underlying disease and the chemotherapy giv-to evaluate the cost effectiveness of itraconazole for en. [3, 4] the prophylaxis of Candida and Aspergillus infecAs invasive fungal infections are associated with tions. The standard pharmacotherapeutic strategy of fluconazole and another common strategy of 'no a high mortality rate, early treatment is required. [5] prophylaxis' were chosen as comparators; other However, the diagnosis of invasive fungal infections antimycotic drugs, such as the newer agents voriis difficult. [6] Therefore, effective antifungal proconazole and caspofungin, are not yet registered for phylaxis is desirable in high-risk patients to reduce the prophylaxis of systemic fungal infection. The morbidity and mortality. So far, the main antifungal clinical management and diagnosis of invasive funagent used for prophylaxis in Europe has been flucogal infections in neutropenic patients is complicated. nazole. However, a major shortcoming of fluconaAs with all models, our model essentially provides a zole is that it lacks activity against Aspergillus spesimplified representation of reality, while still graspcies and many non-albicans Candida species. [7] An ing the most crucial factors in order to validly evalualternative prophylactic antifungal option is itraate the relative cost effectiveness of the antifungal conazole, which has activity against most Candida options. species as well as Aspergillus species. [8] In order to aid decisions concerning which interDecision Model vention provides the best value for limited healthcare resources for antifungal prophylaxis, it is imWe designed a probabilistic model with probabilportant to assess the relative cost effectiveness of ity distributions for the important parameters. The each treatment. As there are no published data com-probabilistic decision model was constructed in paring the cost effectiveness of these antifungal Treeage Data PRO™, version 4.0. The decision agents, the primary objective of this study was to model followed a population of patients treated for assess the cost effectiveness of itraconazole com-haematological malignancies during their neutropared with fluconazole for the prevention of inva-penic period (figure 1). The model provided the following three treatment pathways: (i) no prophy-risks were assumed to be either Normal or triangular laxis; (ii) fluconazole prophylaxis; and (iii) itracona-(when three times the standard deviation exceeded zole prophylaxis. The probability of invasive fungal the mean), as proportions are by definition positive infections in the three arms was taken from studies (table I) . Relative risks for invasive fungal infecincluded in two meta-analyses evaluating the effec-tions during the use of fluconazole or itraconazole tiveness of fluconazole and itraconazole. [7, 8] As in prophylaxis compared with no prophylaxis were the two meta-analyses, we did not make a distinction assumed to follow a lognormal distribution (table for the type of Candida and Aspergillus infection. I). [19] As there is heterogeneity in the trials with regard For fluconazole, the relative risks for invasive to the patient population (e.g. regarding high-and fungal infections compared with no prophylaxis low-risk groups or underlying disease) and study were extracted from the previously mentioned seven design, we used the random effect method of Der-studies. [11] [12] [13] [14] [15] [16] [17] [18] Accordingly, transition probabilities Simonian and Laird [9, 10] to combine the results of the for the fluconazole arm were obtained by multiplydifferent studies. Baseline risks (calculated as the ing the baseline risks for invasive fungal infections number of patients with a certain event divided by with these relative risk estimates. Likewise, risks for the total number of patients) for invasive fungal invasive fungal infections during the use of itraconainfections in the absence of prophylaxis were exzole prophylaxis compared with fluconazole protracted from seven studies comparing high-dose fluphylaxis were obtained by extracting relative risks conazole (400 mg orally or 200 mg intravenously from three studies comparing itraconazole in a [IV]) with placebo or no therapy. [11] [12] [13] [14] [15] [16] [17] [18] For the bioavailable dose of at least 200 mg/day with highmodel, only probable or proven infections were taken into account. Distributions used for baseline dose fluconazole [20] [21] [22] (table I) . Finally, the probabilities of 'no invasive fungal invasive fungal infections (36 Aspergillus, 4 Candiinfection' were obtained by subtracting from 'one' da and 1 Mucor) after receiving itraconazole proboth the probability of candidosis [p(candidosis)] phylaxis, and were matched with 81 reference paand the probability of aspergillosis [p(aspergillosis)] tients (two for each case, except in one case where {i.e. 1 -p(candidosis) -p(aspergillosis)}. In sum-only one adequate match could be found) on undermary, ten studies were used to estimate the risk for lying disease and time of treatment. The infections an invasive fungal infection after antifungal prophy-were either probable or proven. The LOS was calculaxis with itraconazole, fluconazole or no prophy-lated from the first day of chemotherapy until dislaxis.
charge from hospital, or until the start of the second course of chemotherapy.
Costs
For The Netherlands, 29 cases (24 Aspergillus and 5 Candida) and 58 reference patients were obBoth the costs of antifungal prophylaxis and the tained from the Dutch Prismant-database; cases and direct hospital costs associated with the diagnosis, reference patients were matched on ICD-9 diagnosis therapy and increased length of stay (LOS) due to an (204.0 and 205.0) and gender.
[23] The LOS was invasive fungal infection were considered. All costs calculated from the day of admission until diswere reported in €, year 2004 values.
charge. A retrospective cohort study using data for GerCases and references derived from the two many and The Netherlands was carried out to estidatasets were combined to obtain one estimate of the mate the mean increased LOS as a result of an increased LOS associated with an invasive fungal invasive fungal infection in neutropenic patients infection. In this analysis, no distinction was made with haematological malignancies.
between the causative agents as there were too few The German dataset consisted of 178 neutropenic Candida and other infections diagnosed. patients with haematological malignancies (InternaEstimated resource use associated with diagnosis tional Classification of Diseases -10th edition and treatment practices for invasive fungal infec-[ICD-10] codes: C92.0, C91.0, C95.0, C90.0, C81.9 and C83.9). Of these patients, 41 had breakthrough tions in neutropenic patients treated for haemato-logical malignancies were derived from expert clinFinally, national medical unit costs for antifungal treatment, diagnostic tests and hospital stay were ical opinion. This was based on an independent linked to the resources used to estimate the average international panel consisting of three clinicians, cost per Candida or Aspergillus infection [24] [25] [26] [27] [28] [29] (table one from the UK, Germany and The Netherlands. III). These three experts were chosen based on their expertise in the field. The clinicians completed a Cost-Effectiveness Analysis detailed questionnaire on the diagnosis and typical treatment of a Candida or Aspergillus infection. We
The incremental cost effectiveness of itraconaconsidered the individual answers rather than seekzole prophylaxis compared with both fluconazole ing consensus, to enable sensitivity analysis of difprophylaxis and no prophylaxis was estimated. The ferences between experts and countries.
incremental cost-effectiveness ratio (ICER), which As the decision model is a simplification of com-was used as the outcome measure, is defined by plex actual practice, only the main standard diagnos-equation 1: tic tests were included in the economic analysis. Therefore, based on the clinician survey, it was
assumed that a bronchoscopy, two CT scans and (Eq. 1) 13 x-rays (first week every day and thereafter twice where CI and CA are the mean costs per patient in, a week) would be performed for each Aspergillus respectively, the itraconazole group and the alternainfection, and seven diagnostic blood cultures would tive strategy (fluconazole or no prophylaxis) group. be undertaken for each Candida and Aspergillus RI and RA represent the mean risk for an invasive infection.
fungal infection per patient in each group. From this, Treatment practices for invasive fungal infec-effectiveness (E) is defined as the estimated tions as determined by the expert panel in the ques-probability for the absence of an invasive fungal tionnaire are shown in table II. With respect to the infection. Accordingly, cost effectiveness was extreatment options, we averaged the proposed treat-pressed as net costs per invasive fungal infection ment schemes to get one estimate that was a good averted. The perspective for the analysis was that of representation of the average treatment across the the healthcare sector, as only direct medical costs UK, Germany and The Netherlands. We note that were taken into account. Discounting future costs the result is a momentary estimate, which by neces-and health outcomes was not applicable, as the sity is liable to change in response to new informa-model followed patients during their neutropenic tion and the availability of new drugs. The treatment period, which was assumed to be <1 year. was assumed to be IV for 10 days and oral for the
In the baseline analysis, we performed two analyremaining 20 days. However, as amphotericin B ses to estimate the cost effectiveness of itraconazole liposomal (Ambisome ® 1 ) and caspofungin only ex-prophylaxis for Germany and The Netherlands sepaist in the IV-administration form, treatment with rately. For each analysis, we conducted 10 000 these two antifungal agents was assumed to be IV Monte Carlo simulations to fully incorporate the for the full period of 30 days. Potential differences uncertainty associated with the estimated transition in effectiveness between the treatment options were probabilities (second order uncertainty).
[30] The renot taken into account in the model. sults of the Monte Carlo simulations were presented 
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in a cost-effectiveness plane (CE plane). [31] A dominant therapy is clearly to be preferred (southeast quadrant of the CE plane). If a therapy is more effective and higher cost (northeast quadrant of the CE plane), the adoption decision depends on the maximum willingness to pay of decision makers for each unit of additional benefit. In The Netherlands, decision makers use an informal threshold of €20 000 per life-year gained, while for Germany such an explicit threshold does not currently exist. [32] Sensitivity Analyses
To further evaluate the level of uncertainty in the outcomes, a univariate sensitivity analysis (first order uncertainty) was performed. [30] As the clinical management of invasive fungal infections is complex and treatment practices differ widely between different countries and different hospitals, the impact on the cost-effectiveness results of different treatment schemes was assessed. For Germany, we performed an analysis in which we only used the treatment scheme as suggested by the German expert and likewise for The Netherlands.
Furthermore, we investigated sensitivity regarding incidences for aspergillosis and candidosis and treatment modalities for the two invasive fungal infections regarding LOS and treatment duration.
The incidences of invasive fungal infections differ widely among different institutions and, in general, the incidence of Aspergillus infections has been increasing in recent years. We took this into account in the sensitivity analysis by using an equal infection rate for aspergillosis and candidosis (i.e. 0.110 in the absence of prophylaxis).
Because of the limited number of candidosis hospitalizations in our data (n = 9), we were not able to make a reliable distinction in the LOS between Aspergillus and Candida infections. In the sensitivity analysis, we investigated the potential differences in LOS that might exist between the two infections Table II a For Germany we assumed that 90% were socially insured and 10% were privately insured.
b Costs per day based on the doses per day given in the brackets.
c Depending on the exact types of prophylaxis and subsequent treatment (see table II) .
by using unequal additional LOS for Candida and and 2 days of intensive care for a Candida and an Aspergillus infections as suggested in the literature. Aspergillus infection, respectively. Wilson et al. [33] estimated a ratio for additional LOS We also investigated the effect of unequal treatfor a Candida infection versus an Aspergillus infecment lengths for the two types of invasive fungal tion at 14 : 19. In our retrospective study, the excess infections. Torfs [34] noted that the mean duration of LOS was estimated at 11.11 days when only patients with Aspergillus infection were considered. In the antifungal treatment for aspergillosis is considerably sensitivity analysis, this value was input as the ex-longer than that of candidosis. In the sensitivity cess LOS due to Aspergillus infection. We then analysis, we thus prolonged the treatment duration applied the ratio of Wilson et al. [33] and cost saving [ΔC < 0]) compared with both fluconazole and a 'no prophylaxis' scenario. The The mean age was 50 years (range 14-71 years, estimated sampling distributions of the ICERs are n = 139) for the control patients and 53 years (range shown in figure 2 . When comparing itraconazole to 14-71 years, n = 70) for patients with an invasive no prophylaxis, the 95% confidence interval ranges fungal infection. Forty percent of the patients in the from cost saving to approximately €4000 per invareference group and 37% in the case group were sive fungal infection averted for the Dutch situation, female. Most of the patients had acute leukaemia and €5500 for Germany. Due to difficulties in inter-(>95%). The mean LOS for patients with an inva-pretation of a negative ICER, for the comparison of sive fungal infection was 45 ± SD20.8 days, where-itraconazole with fluconazole, we determined the as the mean LOS for control patients was 36 ± 12.5 proportion of the 10 000 Monte Carlo simulations days. Therefore, the mean increase in LOS asso-lying within the southeast quadrant of the CE plane. ciated with an invasive fungal infection in a neutro-As almost 0.98 of the outcomes refer to the southpenic patient treated for haematological malignancy east quadrant, the probability that fluconazole is is estimated as 9.3 days (95% CI 4.5, 13.6). It was dominated by itraconazole is almost 98%. For illusassumed that the increased LOS consisted of 2 days trative purposes, such probabilities for the other in an ICU and the remainder in standard care. [35] comparison are also shown in table V. Additionally, figure 3 presents some detailed inBaseline Analysis formation on the costs averted through itraconazole prophylaxis compared with no prophylaxis and fluThe results of the 10 000 Monte Carlo simula-conazole for The Netherlands. In the former case, tions covering the baseline analysis are given in averted costs on LOS constitute the major share of table IV. The mean cost per patient for prophylaxis savings; in the latter case, averted treatment costs for and the direct medical costs associated with an inva-invasive fungal infections appear to be almost equalsive fungal infection was lower for the itraconazole ly important. This illustrates that, in the absence of arm (The Netherlands: €780, Germany: €785) than prophylaxis, relatively cheap antifungals are used for both the fluconazole arm (The Netherlands: for treatment, whereas this not the case if itracona-€1172, Germany: €1146) and the no prophylaxis zole or fluconazole prophylaxis is chosen. Similar arm (The Netherlands: €928, Germany: €791). The pie charts were found for Germany (not shown mean risk of an invasive fungal infection was lowest here). in patients receiving itraconazole prophylaxis (2.2%), while that risk was almost doubled in the Sensitivity Analysis fluconazole group (4.0%). Patients who did not receive any prophylaxis had a risk of 12.1% for an Instead of averaging the treatment schemes invasive fungal infection. The risk estimates ex-across countries, applying only the treatment tracted from the studies included in the two meta-schemes suggested by the Dutch expert for the analyses, and pooled LOS estimates were applied to Dutch analysis and the German expert for the Gerboth the Dutch and German analyses. Hence, differ-man analysis had only a limited effect on the out- b Only the upper 95% CIs are given because the lower limits always indicated dominance (i.e. CS and more effective); see figure 2.
c Where itraconazole is CS (i.e. both more effective and less costly than the alternative) ICER values are negative and therefore not useful. CI = confidence interval; CS = cost saving (i.e. itraconazole is both more effective and less costly than the alternative strategy); LOS = length of stay.
comes (tables IV and V). For The Netherlands, associated with a small decrease in the mean cost per itraconazole remained dominant to no prophylaxis, patient in all three prophylaxis arms (table IV) . This whilst for Germany there was an incremental cost of also resulted in slightly positive incremental costs €485 to avert an invasive fungal infection compared per infection averted for itraconazole versus no prowith no prophylaxis. For both countries, itracona-phylaxis (The Netherlands: €150 per infection zole remained dominant to fluconazole. averted, Germany: €842 per infection averted; table V). Itraconazole remained dominant to fluconazole The likely difference in LOS between Aspergilin both countries. lus and Candida infections was investigated in the sensitivity analysis. An unequal additional LOS of Furthermore, we investigated the effect of un-11.11 days for aspergillosis and 8.19 days for equal treatment lengths for the two types of infeccandidosis, along with an assumed reduced time in tions by prolonging the treatment duration from intensive care with candidosis (1 day vs 2 days with 30 days up to 40 days in the case of an Aspergillus aspergillosis), was input into the model. This was infection. This had only a small effect on the out- comes (table IV) ; the mean cost per infection avert-both the mean costs and the mean risk for an invasive fungal infection (tables IV and V). Itraconazole ed was slightly increased. In the German situation, became more dominant compared with fluconazole this led to an incremental cost per invasive fungal in both countries. Compared with no prophylaxis, infection averted of €26 for itraconazole versus no itraconazole became more favourable on average as prophylaxis.
well. However, the upper 95% confidence limits Finally, because the incidences of invasive funwere increased (>€150 000) due to an increased gal infections differ widely among different institu-variation in the results. tions, we investigated the effect of assuming equal infection rates for aspergillosis and candidosis (i.e. Discussion 0.110 in the absence of prophylaxis) in the sensitivity analysis. This led to a considerable increase in
We present the first study comparing the cost effectiveness of itraconazole and fluconazole in the prophylaxis of invasive fungal infections in neutropenic patients treated for haematological malignancies. According to our probabilistic decision model, the monetary benefits of averted healthcare exceed the costs of itraconazole prophylaxis under the baseline assumptions; itraconazole is estimated to be cost saving compared with no prophylaxis for The Netherlands (95% CI: from cost saving to a cost of €3972 per invasive fungal infection averted) and Germany (95% CI: from cost saving to €5474 per invasive fungal infection averted). For both countries, itraconazole is also estimated to be both more effective and more economically favourable than fluconazole. The probability that itraconazole domi-€842 per case of invasive fungal infection averted nates fluconazole was estimated at almost 98%. for The Netherlands and Germany, respectively. This means, for The Netherlands, that the prevention For estimating the hospital costs associated with of an invasive fungal infection should at least result an invasive fungal infection, we first performed a in a gain of 3 life-days for the ICER to stay below retrospective cohort study to determine the inthe informal threshold used for assessing value for creased LOS. The increased LOS was estimated at money for national reimbursement purposes of 9.3 days (95% CI 4.5, 13.6). This estimate is slightly €20 000 per life-year gained. [32] This seems a very lower than the 11.3 days estimated by Menzin et moderate gain as invasive fungal infections are assoal. [35] They estimated the increased LOS associated ciated with a high mortality rate. [5] with serious fungal infections among elderly patients diagnosed with acute myeloid leukaemia. ImMoreover, extending the duration of antifungal portant differences, which could, among other treatment for an Aspergillus infection appeared to things, explain the difference in outcome between have only minor influence on the outcomes. Howthe studies were the mean age of the cohorts and the ever, the infection rate did have a considerable effect baseline LOS of the reference group. In the study on the costs and the effects. This could easily be conducted by Menzin et al., [35] the average age of explained by the fact that the cost effectiveness of patients in the study cohort was 73 years, and the preventive strategies such as antifungal prophylaxis baseline LOS of the reference group was 19 days, as always largely depends on the incidence of the parcompared with 51 years and 36 days in our analysis, ticular disease being treated for. Here, the increased respectively.
incidence of aspergillosis on average resulted in more favourable outcomes for itraconazole. NeverSensitivity analyses revealed that varying the key theless, as the variation increased, the upper 95% parameters associated with cost estimation (i.e.
confidence limit exceeded the Dutch threshold of treatment practices obtained from the question-€20 000 per life-year gained when itraconazole was naires, treatment duration and excess LOS) had limcompared with no prophylaxis. ited impact on the cost effectiveness of itraconazole. As the clinical management of invasive fungal in-A probabilistic decision model was produced to fections differs widely among different hospitals, fully incorporate the uncertainty associated with the even within the same country, we performed a sensi-transition probabilities. Even though it is not always tivity analysis on the treatment practices of invasive recognized, the handling of uncertainty in cost-effungal infections. We used the treatment practice as fectiveness models is very important for obtaining suggested by the Dutch expert for the Dutch analysis reliable results.
[30] Another important strength of and likewise for Germany. With the exception of the this study is its use of data obtained from not one, German analysis of itraconazole compared with flu-but several clinical trials to estimate the transition conazole (with an incremental cost of €485 per probabilities in the model. The considerable number invasive fungal infection averted), itraconazole was of patients in each treatment group led to more still estimated to be cost saving compared with both reliable and precise estimates of the probabilities of fluconazole and no prophylaxis. Furthermore, a invasive fungal infections, which increases the valonger excess LOS was assumed for an Aspergillus lidity of the results. Nevertheless, it should be meninfection. Here, the costs of itraconazole prophylax-tioned that absolute baseline risks of Candida and is exceeded the monetary benefits of averted health-Aspergillus infections depend on the setting and can care, producing an incremental cost of €150 and also differ between hospitals within the same coun-try. However, as there are no country-specific data Third, only invasive fungal infections were modfor The Netherlands and Germany, we used a elled. Fluconazole and itraconazole also showed a weighted mean estimate across the clinical trials significant prophylactic effect against superficial used.
fungal infections. [7, 20, 22] Although the treatment of superficial infections is relatively straightforward Study Limitations and inexpensive, reduction in incidence improves quality of life. By not including superficial infecThere are several limitations of our study. tions, the results can be viewed as conservative in Pharmacoeconomic evaluations most often use life-favour of no prophylaxis. However, as no estimates years gained and QALYs as the principal outcome of the costs of superficial infections were identified, measures. However, without survival data for the these costs were not able to be taken into account. patients in this study, it was not possible to provide Finally, we note that it is not necessarily true that reliable estimates of life-years gained. Moreover, it the morbidity and costs incurred due to an invasive may be very difficult to determine invasive fungal fungal infection after either no prophylaxis or with infections as the cause of death. [36] Therefore, we prophylaxis would be similar, as assumed in our used averted invasive fungal infections as the out-model. Unfortunately, we were not able to make this come measure. Furthermore, several parameters distinction with regard to the estimates of the excess could not be included in this model. LOS and treatment duration because the data on First, possible adverse effects and potential dis-these estimates were not stratified according to the continuation of the prophylactic medications were prophylactic agent. not taken into account. Discontinuation was indirectly taken into account as we used the efficacy Conclusions from the intention-to-treat analyses in our metaOn the basis of data from several clinical trials, analysis. We did assume that switching did not lead an international panel of experts and Dutch and to an increase in the length of prophylactic treatment German resource costing, the model suggests that and thus the costs. In general, itraconazole and fluitraconazole is likely to result in improved outcomes conazole are well tolerated. [8] Nevertheless, the disand lower costs compared with fluconazole and no continuation rate appears to be higher for itraconaprophylaxis for both The Netherlands and Germany. zole compared with fluconazole, discontinuation beTherefore, in specific groups of neutropenic patients ing most often due to gastrointestinal problems. [20] [21] [22] treated for haematological malignancies, itraconaSo, inclusion of discontinuation in the model is zole prophylaxis could potentially reduce overall likely to have little influence on the cost estimates.
healthcare expenditure in settings where fluconazole The same may hold true for the inclusion of treatis common practice in the prophylaxis of invasive ment for adverse effects, as the related costs are fungal infections. minor. [37] Second, switching in the treatment of probable or 
